⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TVTX News
Travere Therapeutics, Inc. Common Stock
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63 rd European Renal Association (ERA) 2026 Congress
businesswire.com
TVTX
Form 8-K
sec.gov
TVTX
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI ® (sparsentan) in IgA Nephropathy
businesswire.com
TVTX
Form 8-K
sec.gov
TVTX
Form 8-K
sec.gov
TVTX
Travere Therapeutics to Participate at Upcoming Investor Conferences
businesswire.com
TVTX
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
businesswire.com
TVTX
Form 8-K
sec.gov
TVTX
Travere Therapeutics Reports First Quarter 2026 Financial Results
businesswire.com
TVTX
Purespring announces publication of notable study highlighting an under recognised genetic driver of adult-onset FSGS, in particular in US and UK populations
globenewswire.com
TVTX
NTRA